<DOC>
	<DOCNO>NCT01901224</DOCNO>
	<brief_summary>The investigator research study find take Metformin improve walk ability patient peripheral arterial disease ( PAD ) . In PAD artery ( blood vessel ) legs narrow build plaque . The leg muscle hurt patient PAD usually describe cramp tiredness . This pain call intermittent claudication . Metformin FDA approve medication treatment diabetes . The investigator believe Metformin may help leg muscle work well . The investigator enroll 100 subject order find 60 subject PAD Brigham Women 's Hospital ( BWH ) .</brief_summary>
	<brief_title>Metformin , Muscle Energetics , Vascular Function Older Adults With Peripheral Artery Disease</brief_title>
	<detailed_description>Peripheral artery disease ( PAD ) manifestation atherosclerosis affect 7 million adult US . The prevalence PAD increase age estimate 15 20 % among individual 65 year age old . Patients PAD limit functional capacity ; walk slowly less walking endurance person PAD , irrespective whether classic symptom intermittent claudication critical limb ischemia . This functional impairment adversely affect quality life . Although flow limitation due atherosclerotic stenosis necessary development symptom PAD , lack correlation walk capacity degree hemodynamic compromise raise possibility alternative mechanism contribute functional limitation patient . Putative mechanism include inadequate skeletal muscle glucose uptake , alter skeletal muscle energetics , impaired vasomotor tone nutrient delivery mediate endothelial dysfunction . Metformin , via AMPactivated protein kinase ( AMPK ) -dependent independent mechanism , favorably affect skeletal muscle metabolic function include glucose uptake , fatty acid oxidation , mitochondrial function , consequently cellular energetics , also may direct salutary effect vascular function via regulation nitric oxide synthase . It intriguing , therefore , consider possibility metformin would improve skeletal muscle metabolic vascular function old patient PAD translate functional benefit . Accordingly , investigator seek elucidate molecular mechanism metformin affect skeletal muscle energetics hypothesize metformin lead advantageous metabolic , vascular , physical functional change older patient PAD .</detailed_description>
	<mesh_term>Peripheral Arterial Disease</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>Age 40 year great Intermittent claudication 6 month great Maximal walk time 120 minute ETTs Resting ABI ≤ 0.9 index leg baseline ABI fall ≥ 20 % index leg 1 minute post baseline ETT MWT variability &lt; 20 % Type 1 Type 2 Diabetes Limbthreatening ischemia ( rest pain , ulceration , gangrene ) Peripheral vascular surgery PCI within 6 month MI CABG within 6 month Carotid endarterectomy ( CEA ) within 6 month Cerebrovascular accident TIA within 6 month Uncontrolled hypertension ( SBP &gt; 140 mmHg , DBP &gt; 90 mmHg ) Pentoxifylline/Cilostazol added/changed within 3 month HMGCoA reductase inhibitor added/changed within 3 month Exercise limitation claudication ( heart failure , angina , COPD , arthritis , neuropathy , etc . ) Serum creatinine ≥ 1.5 mg/dL Pregnant plan become pregnant 2 hour Oral Glucose Tolerance Test ( OGTT ) &gt; 200 mg/dL</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2015</verification_date>
</DOC>